Every system at Lazent Clinical is designed to meet or exceed the standards set by the world's most rigorous regulatory agencies. Quality is built into our infrastructure, SOPs, and culture from day one.
Regulatory Standards & Compliance Framework
Every data point generated at Lazent Clinical is traceable, auditable, and meets ALCOA+ principles for regulatory submission.
Project timelines are rigorously managed with milestone tracking and proactive escalation for every study we conduct.
Participant safety is our highest priority. ICU-level monitoring, 24/7 medical cover, and IEC-approved protocols at all times.
Our SOPs, audit trails, and documentation are structured to withstand US FDA and EMA inspection at any moment.
From founding to global regulatory readiness — the milestones that define Lazent Clinical's growth story.
Lazent Clinical established in Chennai with a mandate to deliver US/EU-grade CRO services from India — bringing global standards to a cost-efficient hub.
Full GCP and GLP-compliant operations activated across clinical and bioanalytical divisions — laying the foundation for global sponsor confidence.
State-of-the-art clinical unit launched with 110+ beds, full ICU monitoring capability, dedicated dosing stations, and 24/7 medical supervision infrastructure.
LC-MS/MS bioanalytical facility commissioned — capable of validated quantitative analysis for global ANDA submissions under GCLP compliance.
First formal step toward US FDA regulatory inspection readiness — facility registration initiated with documentation and SOP alignment to 21 CFR standards.
DCGI/CDSCO regulatory approval application submitted for clinical site authorization to conduct Phase II–IV studies in India.
National Accreditation Board for Testing and Calibration Laboratories (NABL) process formally commenced for the bioanalytical laboratory.
First US ANDA-linked BA/BE study initiated — a landmark milestone in global sponsor partnership, validating Lazent Clinical's readiness for international pharmaceutical development.
Facility at a Glance
Our near-term and long-term roadmap reflects commitment to expanding capabilities and earning global regulatory recognition.
Clear first US FDA GCP/GLP audit with zero 483 observations.
Complete accreditation for the bioanalytical laboratory.
Obtain site authorization to expand Phase II–IV studies.
More beds and additional LC-MS/MS instruments for growing volumes.
Strengthen US presence to directly serve ANDA sponsors.
Formal partnerships with EU CRO networks and US academic centres.
Achieve WHO PQ recognition for global health programs.
Dedicated unit with oncology and CNS monitoring capabilities.
Population PK, PBPK modelling, and biomarker discovery.